Business Wire

TYAN Powers AI and HPC with 2nd Gen Intel® Xeon® Scalable Processor-based Server Platforms at ISC 2019

Share

TYAN®, an industry-leading server platform design manufacturer and a MiTAC Computing Technology Corporation subsidiary, is showcasing its new 2nd gen Intel® Xeon® Scalable processor-based platforms that are optimized for predictive analytics, machine learning, and HPC applications at ISC 2019 from June 17-19 at Messe Frankfurt, booth C-1250.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190617005020/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

TYAN's Thunder HX Lineup Designed for AI Optimization and HPC Revolution (Photo: Business Wire)

“The most demanding workloads including HPC, AI deep learning, data analytics, and multi-cloud infrastructure require maximum performance across compute, memory, storage, and network resources, “said Danny Hsu, Vice President of MiTAC Computing Technology Corporation's TYAN Business Unit. “2nd gen Intel Xeon Scalable processors provide a powerful foundation for TYAN server platforms that enables us to deliver performance enhancements across a broad variety of application scenarios.”

Powered by the newest generation of Intel Xeon Scalable processors, TYAN's Thunder HX lineup takes advantage of Intel® Deep Learning Boost technology to enable faster machine learning application execution. The new Thunder HX FT83-B7119 supports 3TB of memory, 12 hot-swappable 3.5” drives in a 4U enclosure. The system is ideal for AI training and inference applications. The Thunder HX FT77D-B7109 is another 4U server system on display that supports dual 2nd gen Intel Xeon Scalable processors with integrated Intel® Omni-Path 100 gigabit networking fabric that can reach a total of 200Gb/s fabric connectivity for massively parallel workloads such as scientific computing and large-scale facial recognition.

TYAN's Thunder HX FT48T-B7105 is a pedestal workstation platform with dual 2nd gen Intel Xeon Scalable processors and supports for up to 5 high performance workstation graphic cards. This high-end workstation gives maximum I/O to professional power users, and is a great platform for 3D rendering and image processing.

Benefitted by Intel® Optane™ DC persistent memory, and increased DDR4 memory speed and capacity, TYAN’s storage server platforms with the 2nd gen Intel Xeon Scalable processors are able to deliver amazing performance. The Thunder SX FA100-B7118 is TYAN's flagship storage server supporting dual 2nd gen Intel Xeon Scalable processors and 100 hot-swap 3.5" drives in a 4U rackmount form factor. The platform is designed for both cold storage and large-scale object storage applications such as Lustre. The new Thunder SX GT90-B7113 features support for dual 2nd gen Intel Xeon Scalable processors, 12 hot-swap 3.5” drives mounted to a service drawer and 4 hot-swap NVMe U.2 drive bays in a 35” deep 1U chassis. The platform perfectly matches CSP server-based storage applications by allowing serviceability and density within the same server.

“Data is the currency of the new digital economy, and how effectively organizations move, store and process it will help determine their level of success,” said Jennifer Huffstetler, vice president and general manager of Datacenter Product Management and Storage at Intel. “Intel technologies like 2nd Gen Intel Xeon Scalable processors, Intel DL Boost and Intel Optane DC persistent memory will be key in turning raw data into actionable insights.”

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

MiTAC Computing Technology Corporation/ TYAN Business Unit
Fenny Chen
fenny.chen@tyan.com.tw

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 03:09:00 EEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio ha

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 23:06:00 EEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye